{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:57:18Z","timestamp":1793750238888,"version":"4.6.1"},"reference-count":116,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDRR"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>SGLT2 (Sodium-Glucose Co-transporter 2) inhibitors, also known as gliflozin class,\nare a novel family of oral drugs being used to treat type 2 diabetes. SGLT2 inhibitors can work\nalone or in conjunction with other medications. This class includes five drugs, including canagliflozin,\nertugliflozin, sotagliflozin, dapagliflozin, and empagliflozin. SGLT2 inhibitors inhibit the\nSGLT2 cotransporter in the proximal tubules of the kidney, reducing glucose and sodium reabsorption.\nIt promotes the elimination of sugar in urine (diabetes mellitus) and lowers blood sugar levels.\nSGLT2 inhibitors also have pleiotropic effects on cardiac and renal function, broadening their\ntherapeutic applications in heart failure. Despite the clinical benefits, regulators have placed secondary\nwarnings in product information since the medications first hit the market. SGLT2 inhibitors,\nin particular, have had a significant impact on a variety of risk factors. This can lead to hypoglycaemia,\nurinary tract infections, diabetic ketoacidosis, lower limb amputation, and fractures. Although\nsome of these events are uncommon, they can lead to severe and deadly consequences;\ntherefore, patients must be closely monitored. In general, SLGT2 inhibitors are an efficient diabetes\ntreatment with strong cardiovascular and renal protection and a favourable safety overview.\nThis review sought to summarise the safety overview of commercially available SGLT2 inhibitors.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0125899775332399240806101923","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T06:04:42Z","timestamp":1724133882000},"page":"19-32","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Insightful Perspectives on Sodium-glucose Co-transporter 2 Inhibitors: Navigating Safety Updates and Beyond"],"prefix":"10.2174","volume":"17","author":[{"given":"Pratikeswar","family":"Panda","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmaceutical Science, Siksha 'O' Anusandhan University, Bhubaneswar,\nOdisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajaram","family":"Mohapatra","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmaceutical Science, Siksha 'O' Anusandhan University, Bhubaneswar,\nOdisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biswajit","family":"Samantaray","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmaceutical Science, Siksha 'O' Anusandhan University, Bhubaneswar,\nOdisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1007\/s00125-018-4656-5","volume":"61","author":"Ghezzi C.","year":"2018","unstructured":"Ghezzi C.; Loo D.D.F.; Wright E.M.; Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2. Diabetologia  2018,61(10),2087-2097","journal-title":"Diabetologia"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.2337\/dc15-0642","volume":"38","author":"Mudaliar S.","year":"2015","unstructured":"Mudaliar S.; Polidori D.; Zambrowicz B.; Henry R.R.; Sodiumglucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside. Diabetes Care  2015,38(12),2344-2353","journal-title":"Diabetes Care"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/1479164114561992","volume":"12","author":"Gallo L.A.","year":"2015","unstructured":"Gallo L.A.; Wright E.M.; Vallon V.; Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences. Diab Vasc Dis Res  2015,12(2),78-89","journal-title":"Diab Vasc Dis Res"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/MNH.0000000000000152","volume":"24","author":"Poulsen S.B.","year":"2015","unstructured":"Poulsen S.B.; Fenton R.A.; Rieg T.; Sodium-glucose cotransport. Curr Opin Nephrol Hypertens  2015,24(5),463-469","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"F188","DOI":"10.1152\/ajprenal.00518.2013","volume":"306","author":"Rieg T.","year":"2014","unstructured":"Rieg T.; Masuda T.; Gerasimova M.; Increase in SGLT1-mediated trans-port explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Renal Physiol  2014,306,F188-F193","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"412","DOI":"10.2337\/dc13-2955","volume":"38","author":"Henry R.R.","year":"2015","unstructured":"Henry R.R.; Rosenstock J.; Edelman S.; Mudaliar S.; Chalamandaris A.G.; Kasichayanula S.; Bogle A.; Iqbal N.; List J.; Griffen S.C.; Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care  2015,38(3),412-419","journal-title":"Diabetes Care"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1111\/dom.13003","volume":"19","author":"Norton L.","year":"2017","unstructured":"Norton L.; Shannon C.E.; Fourcaudot M.; Hu C.; Wang N.; Ren W.; Song J.; Abdul-Ghani M.; DeFronzo R.A.; Ren J.; Jia W.; \u00a0 Sodium-glucose \u00a0 co-transporter () and glucose transporter () expression in the kidney of type 2 diabetic subjects. Diabetes Obes Metab  2017,19(9),1322-1326","journal-title":"Diabetes Obes Metab"},{"key":"ref=8","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12970","author":"Solini A.","year":"2017","unstructured":"Solini A.; Rossi C.; Mazzanti C.M.; Proietti A.; Koepsell H.; Ferrannini E.; You have full text access to this contentSGLT2 and SGLT1 renal expression in patients with type 2 diabetes. Diabetes Obes Metab  2017","journal-title":"Diabetes Obes Metab"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"5335","DOI":"10.1074\/jbc.M117.779520","volume":"292","author":"Wang X.X.","year":"2017","unstructured":"Wang X.X.; Levi J.; Luo Y.; Myakala K.; Herman-Edelstein M.; Qiu L.; Wang D.; Peng Y.; Grenz A.; Lucia S.; Dobrinskikh E.; D\u2019Agati V.D.; Koepsell H.; Kopp J.B.; Rosenberg A.Z.; Levi M.; SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy. J Biol Chem  2017,292(13),5335-5348","journal-title":"J Biol Chem"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"F317","DOI":"10.1152\/ajprenal.00145.2014","volume":"307","author":"Gembardt F.","year":"2014","unstructured":"Gembardt F.; Bartaun C.; Jarzebska N.; Mayoux E.; Todorov V.T.; Hohenstein B.; Hugo C.; The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob\/ob type 2 diabetic mice with and without hypertension. Am J Physiol Renal Physiol  2014,307(3),F317-F325","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1507\/endocrj.EJ17-0065","volume":"64","author":"Takebayashi K.","year":"2017","unstructured":"Takebayashi K.; Hara K.; Terasawa T.; Naruse R.; Suetsugu M.; Tsuchiya T.; Inukai T.; Effect of canagliflozin on circulating active GLP-1 levels in patients with type 2 diabetes: a randomized trial. Endocr J  2017,64(9),923-931","journal-title":"Endocr J"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"700","DOI":"10.2215\/CJN.06080616","volume":"12","author":"van Bommel E.J.M.","year":"2017","unstructured":"van Bommel E.J.M.; Muskiet M.H.A.; Tonneijck L.; Kramer M.H.H.; Nieuwdorp M.; van Raalte D.H.; SGLT2 inhibition in the diabetic kidneyfrom mechanisms to clinical outcome. Clin J Am Soc Nephrol  2017,12(4),700-710","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"C14","DOI":"10.1152\/ajpcell.00388.2010","volume":"300","author":"Hummel C.S.","year":"2011","unstructured":"Hummel C.S.; Lu C.; Loo D.D.F.; Hirayama B.A.; Voss A.A.; Wright E.M.; Glucose transport by human renal Na \/ -glucose cotransporters SGLT1 and SGLT2. Am J Physiol Cell Physiol  2011,300(1),C14-C21","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3390\/toxins14030210","volume":"14","author":"Evenepoel P.","year":"2022","unstructured":"Evenepoel P.; Meijers B.; Masereeuw R.; Lowenstein J.; Effects of an SGLT inhibitor on the production, toxicity, and elimination of gutderived uremic toxins: a call for additional evidence. Toxins (Basel)  2022,14(3),210","journal-title":"Toxins (Basel)"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.2147\/DDDT.S50773","volume":"8","author":"Nauck M.","year":"2014","unstructured":"Nauck M.; Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther  2014,8,1335-1380","journal-title":"Drug Des Devel Ther"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"777861","DOI":"10.3389\/fmed.2021.777861","volume":"8","author":"Fonseca-Correa J.I.","year":"2021","unstructured":"Fonseca-Correa J.I.; Correa-Rotter R.; Sodium-glucose cotransporter 2 inhibitors mechanisms of action: a review. Front Med (Lausanne)  2021,8,777861","journal-title":"Front Med (Lausanne)"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nrneph.2012.19","volume":"8","author":"Helal I.","year":"2012","unstructured":"Helal I.; Fick-Brosnahan G.M.; Reed-Gitomer B.; Schrier R.W.; Glomerular hyperfiltration: definitions, mechanisms and clinical implications. Nat Rev Nephrol  2012,8(5),293-300","journal-title":"Nat Rev Nephrol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.cmet.2021.02.016","volume":"33","author":"Sen T.","year":"2021","unstructured":"Sen T.; Heerspink H.J.L.; A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors. Cell Metab  2021,33(4),732-739","journal-title":"Cell Metab"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1056\/NEJMoa1614329","volume":"376","author":"Denic A.","year":"2017","unstructured":"Denic A.; Mathew J.; Lerman L.O.; Lieske J.C.; Larson J.J.; Alexander M.P.; Poggio E.; Glassock R.J.; Rule A.D.; Single-nephron glomerular filtration rate in healthy adults. N Engl J Med  2017,376(24),2349-2357","journal-title":"N Engl J Med"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.kint.2017.04.010","volume":"92","author":"Lim B.J.","year":"2017","unstructured":"Lim B.J.; Yang J.W.; Zou J.; Zhong J.; Matsusaka T.; Pastan I.; Zhang M.Z.; Harris R.C.; Yang H.C.; Fogo A.B.; Tubulointerstitial fibrosis can sensitize the kidney to subsequent glomerular injury. Kidney Int  2017,92(6),1395-1403","journal-title":"Kidney Int"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1007\/s12325-021-01735-5","volume":"38","author":"Mima A.","year":"2021","unstructured":"Mima A.; Sodium-glucose cotransporter 2 inhibitors in patients with non-diabetic chronic kidney disease. Adv Ther  2021,38(5),2201-2212","journal-title":"Adv Ther"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"F227","DOI":"10.1152\/ajprenal.00689.2014","volume":"309","author":"O\u2019Neill J.","year":"2015","unstructured":"O\u2019Neill J.; Fasching A.; Pihl L.; Patinha D.; Franz\u00e9n S.; Palm F.; Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. Am J Physiol Renal Physiol  2015,309(3),F227-F234","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"R75","DOI":"10.1152\/ajpregu.00357.2011","volume":"302","author":"Thomson SC.","year":"2012","unstructured":"Thomson SC.; Rieg T.; Miracle C.; Mansoury H.; Whaley J.; Vallon V; Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol  2012,302(1),R75-R83","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"F969","DOI":"10.1152\/ajprenal.00551.2017","volume":"314","author":"Layton AT.","year":"2018","unstructured":"Layton AT.; Vallon V.; SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism. Am J Physiol Renal Physiol  2018,314(5),F969-F984","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","volume":"129","author":"Cherney D.Z.I.","year":"2014","unstructured":"Cherney D.Z.I.; Perkins B.A.; Soleymanlou N.; Maione M.; Lai V.; Lee A.; Fagan N.M.; Woerle H.J.; Johansen O.E.; Broedl U.C.; von Eynatten M.; Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation  2014,129(5),587-597","journal-title":"Circulation"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/dom.12090","volume":"15","author":"Yale J.F.","year":"2013","unstructured":"Yale J.F.; Bakris G.; Cariou B.; Yue D.; David-Neto E.; Xi L.; Figueroa K.; Wajs E.; Usiskin K.; Meininger G.; Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab  2013,15(5),463-473","journal-title":"Diabetes Obes Metab"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12933-020-01071-y","volume":"19","author":"Ni L.","year":"2020","unstructured":"Ni L.; Yuan C.; Chen G.; Zhang C.; Wu X.; SGLT2i: beyond the glucose-lowering effect. Cardiovasc Diabetol  2020,19(1),98","journal-title":"Cardiovasc Diabetol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2337\/dc16-0542","volume":"39","author":"Mudaliar S.","year":"2016","unstructured":"Mudaliar S.; Alloju S.; Henry R.R.; Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG outcome study? A unifying hypothesis. Diabetes Care  2016,39(7),1115-1122","journal-title":"Diabetes Care"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/MNH.0000000000000343","volume":"26","author":"Rajasekeran H.","year":"2017","unstructured":"Rajasekeran H.; Cherney D.Z.; Lovshin J.A.; Do effects of sodium\u2013glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease? Curr Opin Nephrol Hypertens  2017,26(5),358-367","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.2337\/db13-0604","volume":"62","author":"Abdul-Ghani M.A.","year":"2013","unstructured":"Abdul-Ghani M.A.; DeFronzo R.A.; Norton L.; Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. Diabetes  2013,62(10),3324-3328","journal-title":"Diabetes"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jdiacomp.2018.04.011","volume":"32","author":"Mima A.","year":"2018","unstructured":"Mima A.; Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease. J Diabetes Complications  2018,32(7),720-725","journal-title":"J Diabetes Complications"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s00125-015-3547-2","volume":"58","author":"Cefalu W.T.","year":"2015","unstructured":"Cefalu W.T.; Stenl\u00f6f K.; Leiter L.A.; Wilding J.P.H.; Blonde L.; Polidori D.; Xie J.; Sullivan D.; Usiskin K.; Canovatchel W.; Meininger G.; Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. Diabetologia  2015,58(6),1183-1187","journal-title":"Diabetologia"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1111\/ijcp.12675","volume":"69","author":"Brunton S.A.","year":"2015","unstructured":"Brunton S.A.; The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus. Int J Clin Pract  2015,69(10),1071-1087","journal-title":"Int J Clin Pract"},{"key":"ref=34","year":"2016","unstructured":"Prescribing information, INVOKANA.  Available from:  http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/204042s011lbl.pdf(accessed on 31-7-2024)2016"},{"key":"ref=35","year":"2015","unstructured":"Prescribing information, FARXIGA.  Available from:  http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/202293s008lbl.pdf(accessed on 31-7-2024)2015"},{"key":"ref=36","year":"2016","unstructured":"Prescribing information, JARDIANCE.  Available from:  http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/204629s005lbl.pdf(accessed on 31-7-2024)2016"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1517\/14740338.2015.1100167","volume":"14","author":"Scheen A.J.","year":"2015","unstructured":"Scheen A.J.; SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment. Expert Opin Drug Saf  2015,14(12),1879-1904","journal-title":"Expert Opin Drug Saf"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s00228-014-1730-x","volume":"70","author":"Yang XP.","year":"2014","unstructured":"Yang XP.; Lai D.; Zhong XY.; Shen HP.; Huang YL.; Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis. Eur J Clin Pharmacol  2014,70,1149-1158","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/dmrr.2479","volume":"30","author":"Zhang M.","year":"2014","unstructured":"Zhang M.; Zhang L.; Wu B.; Song H.; An Z.; Li S.; Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev  2014,30(3),204-221","journal-title":"Diabetes Metab Res Rev"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1111\/dom.12307","volume":"16","author":"Liakos A.","year":"2014","unstructured":"Liakos A.; Karagiannis T.; Athanasiadou E.; Sarigianni M.; Mainou M.; Papatheodorou K.; Bekiari E.; Tsapas A.; Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab  2014,16(10),984-993","journal-title":"Diabetes Obes Metab"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"Zinman B.","year":"2015","unstructured":"Zinman B.; Wanner C.; Lachin J.M.; Fitchett D.; Bluhmki E.; Hantel S.; Mattheus M.; Devins T.; Johansen O.E.; Woerle H.J.; Broedl U.C.; Inzucchi S.E.; Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med  2015,373(22),2117-2128","journal-title":"N Engl J Med"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.clinthera.2016.03.031","volume":"38","author":"Kohler S.","year":"2016","unstructured":"Kohler S.; Salsali A.; Hantel S.; Kaspers S.; Woerle H.J.; Kim G.; Broedl U.C.; Safety and tolerability of empagliflozin in patients with type 2 diabetes. Clin Ther  Epub ahead of print2016,38(6),1299-1313","journal-title":"Clin Ther"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.diabres.2013.12.052","volume":"103","author":"Geerlings S.","year":"2014","unstructured":"Geerlings S.; Fonseca V.; Castro-Diaz D.; List J.; Parikh S.; Genital and urinary tract infections in diabetes: Impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract  2014,103(3),373-381","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1185\/03007995.2012.697053","volume":"28","author":"Nyirjesy P.","year":"2012","unstructured":"Nyirjesy P.; Zhao Y.; Ways K.; Usiskin K.; Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin  2012,28(7),1173-1178","journal-title":"Curr Med Res Opin"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jdiacomp.2013.04.012","volume":"27","author":"Johnsson K.M.","year":"2013","unstructured":"Johnsson K.M.; Ptaszynska A.; Schmitz B.; Sugg J.; Parikh S.J.; List J.F.; Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications  2013,27(5),479-484","journal-title":"J Diabetes Complications"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.clinthera.2015.03.004","volume":"37","author":"Whalen K.","year":"2015","unstructured":"Whalen K.; Miller S.; Onge E.S.; The role of sodium-glucose co-transporter 2 inhibitors in the treatment of type 2 diabetes. Clin Ther  2015,37(6),1150-1166","journal-title":"Clin Ther"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1185\/03007995.2014.890925","volume":"30","author":"Nyirjesy P.","year":"2014","unstructured":"Nyirjesy P.; Sobel J.D.; Fung A.; Mayer C.; Capuano G.; Ways K.; Usiskin K.; Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin  2014,30(6),1109-1119","journal-title":"Curr Med Res Opin"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1517\/14656566.2016.1109629","volume":"17","author":"Parveen R.","year":"2016","unstructured":"Parveen R.; Agarwal N.B.; Kaushal N.; Mali G.; Raisuddin S.; Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials. Expert Opin Pharmacother  2016,17(1),105-115","journal-title":"Expert Opin Pharmacother"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s40264-014-0213-4","volume":"37","author":"Ptaszynska A.","year":"2014","unstructured":"Ptaszynska A.; Johnsson K.M.; Parikh S.J.; de Bruin T.W.A.; Apanovitch A.M.; List J.F.; Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events. Drug Saf  2014,37(10),815-829","journal-title":"Drug Saf"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/dom.12428","volume":"17","author":"Bode B.","year":"2015","unstructured":"Bode B.; Stenl\u00f6f K.; Harris S.; Sullivan D.; Fung A.; Usiskin K.; Meininger G.; Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55\u201380 years with type 2 diabetes. Diabetes Obes Metab  2015,17(3),294-303","journal-title":"Diabetes Obes Metab"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s40262-015-0264-4","volume":"54","author":"Scheen A.J.","year":"2015","unstructured":"Scheen A.J.; Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease. Clin Pharmacokinet  2015,54(7),691-708","journal-title":"Clin Pharmacokinet"},{"key":"ref=52","first-page":"S1","volume":"39","year":"2002","unstructured":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis  2002,39(2)(Suppl. 1),S1-S266","journal-title":"Am J Kidney Dis"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","volume":"2","author":"Barnett A.H.","year":"2014","unstructured":"Barnett A.H.; Mithal A.; Manassie J.; Jones R.; Rattunde H.; Woerle H.J.; Broedl U.C.; Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol  2014,2(5),369-384","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s40620-016-0261-1","volume":"29","author":"Kohan D.E.","year":"2016","unstructured":"Kohan D.E.; Fioretto P.; Johnsson K.; Parikh S.; Ptaszynska A.; Ying L.; The effect of dapagliflozin on renal function in patients with type 2 diabetes. J Nephrol  Epub ahead of print2016,29(3),391-400","journal-title":"J Nephrol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1185\/03007995.2015.1092128","volume":"31","author":"Perkovic V.","year":"2015","unstructured":"Perkovic V.; Jardine M.; Vijapurkar U.; Meininger G.; Renal effects of canagliflozin in type 2 diabetes mellitus. Curr Med Res Opin  2015,31(12),2219-2231","journal-title":"Curr Med Res Opin"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1177\/2042018814560735","volume":"6","author":"Liakos A.","year":"2015","unstructured":"Liakos A.; Karagiannis T.; Bekiari E.; Boura P.; Tsapas A.; Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab  2015,6(2),61-67","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref=57","unstructured":"US Food and Drug Administration. Drug safety communications : FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood.  Available from:  http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM446954.pdf(accessed on 31-7-2024)"},{"key":"ref=58","unstructured":"EMA confirms recommendations to minimise ketoacidosis risk with SGLT2 inhibitors for diabetes.  Available from:  http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/referrals\/SG LT2_inhibitors\/human_referral_prac_000052.jspandmid=WC0b01ac05805c516f(accessed on 31-7-2024)"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/dom.13124","volume":"20","author":"Jabbour S.","year":"2018","unstructured":"Jabbour S.; Seufert J.; Scheen A.; Bailey C.J.; Karup C.; Langkilde A.M.; Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb\/III clinical trials. Diabetes Obes Metab  2018,20(3),620-628","journal-title":"Diabetes Obes Metab"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.2337\/dc15-1251","volume":"38","author":"Erondu N.","year":"2015","unstructured":"Erondu N.; Desai M.; Ways K.; Meininger G.; Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care  2015,38(9),1680-1686","journal-title":"Diabetes Care"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.diabres.2017.04.017","volume":"130","author":"Monami M.","year":"2017","unstructured":"Monami M.; Nreu B.; Zannoni S.; Lualdi C.; Mannucci E.; Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials. Diabetes Res Clin Pract  2017,130,53-60","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"Wiviott S.D.","year":"2019","unstructured":"Wiviott S.D.; Raz I.; Bonaca M.P.; Mosenzon O.; Kato E.T.; Cahn A.; Silverman M.G.; Zelniker T.A.; Kuder J.F.; Murphy S.A.; Bhatt D.L.; Leiter L.A.; McGuire D.K.; Wilding J.P.H.; Ruff C.T.; Gause-Nilsson I.A.M.; Fredriksson M.; Johansson P.A.; Langkilde A.M.; Sabatine M.S.; Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med  2019,380(4),347-357","journal-title":"N Engl J Med"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.diabres.2017.04.004","volume":"128","author":"Wang Y.","year":"2017","unstructured":"Wang Y.; Desai M.; Ryan P.B.; DeFalco F.J.; Schuemie M.J.; Stang P.E.; Berlin J.A.; Yuan Z.; Incidence of diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors and other antihyperglycemic agents. Diabetes Res Clin Pract  2017,128,83-90","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1056\/NEJMc1701990","volume":"376","author":"Fralick M.","year":"2017","unstructured":"Fralick M.; Schneeweiss S.; Patorno E.; Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med  2017,376(23),2300-2302","journal-title":"N Engl J Med"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1111\/dom.13297","volume":"20","author":"Kim Y.G.","year":"2018","unstructured":"Kim Y.G.; Jeon J.Y.; Han S.J.; Kim D.J.; Lee K.W.; Kim H.J.; Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus:  nationwide population-based cohort study. Diabetes Obes Metab  2018,20(8),1852-1858","journal-title":"Diabetes Obes Metab"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.2337\/dc16-2793","volume":"40","author":"Jensen M.L.","year":"2017","unstructured":"Jensen M.L.; Persson F.; Andersen G.S.; Ridderstr\u00e5le M.; Nolan J.J.; Carstensen B.; J\u00f8rgensen M.E.; Incidence of ketoacidosis in the Danish type 2 diabetes population before and after introduction of sodium-glucose cotransporter 2 inhibitors-A nationwide, retrospective cohort study, 1995-2014. Diabetes Care  2017,40(5),e57-e58","journal-title":"Diabetes Care"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"k4365","DOI":"10.1136\/bmj.k4365","volume":"363","author":"Ueda P.","year":"2018","unstructured":"Ueda P.; Svanstr\u00f6m H.; Melbye M.; Eliasson B.; Svensson A.M.; Franz\u00e9n S.; Gudbj\u00f6rnsdottir S.; Hveem K.; Jonasson C.; Pasternak B.; Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ  2018,363,k4365","journal-title":"BMJ"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s00125-017-4301-8","volume":"60","author":"Fadini G.P.","year":"2017","unstructured":"Fadini G.P.; Bonora B.M.; Avogaro A.; SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologia  2017,60(8),1385-1389","journal-title":"Diabetologia"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"e2924","DOI":"10.1002\/dmrr.2924","volume":"33","author":"Blau J.E.","year":"2017","unstructured":"Blau J.E.; Tella S.H.; Taylor S.I.; Rother K.I.; Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data. Diabetes Metab Res Rev  2017,33(8),e2924","journal-title":"Diabetes Metab Res Rev"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2147\/IJNRD.S135899","volume":"10","author":"D\u2019Elia J.","year":"2017","unstructured":"D\u2019Elia J.; Segal A.; Bayliss G.; Weinrauch L.; Sodium\u2013glucose cotransporter-2 inhibition and acidosis in patients with type 2 diabetes: a review of US FDA data and possible conclusions. Int J Nephrol Renovasc Dis  2017,10,153-158","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.2337\/dc17-1721","volume":"41","author":"Meyer E.J.","year":"2018","unstructured":"Meyer E.J.; Gabb G.; Jesudason D.; SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis: a South Australian clinical case series and Australian spontaneous adverse event notifications. Diabetes Care  2018,41(4),e47-e49","journal-title":"Diabetes Care"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/fcp.12334","volume":"32","author":"Ado Moumouni A.N.","year":"2018","unstructured":"Ado Moumouni A.N.; Robin P.; Hillaire-Buys D.; Faillie J.L.; -2 inhibitors and ketoacidosis: a disproportionality analysis in the World Health Organization\u2019s adverse drug reactions database. Fundam Clin Pharmacol  2018,32(2),216-226","journal-title":"Fundam Clin Pharmacol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.2337\/dc15-0843","volume":"38","author":"Peters A.L.","year":"2015","unstructured":"Peters A.L.; Buschur E.O.; Buse J.B.; Cohan P.; Diner J.C.; Hirsch I.B.; Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care  2015,38(9),1687-1693","journal-title":"Diabetes Care"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/jdi.12401","volume":"7","author":"Ogawa W.","year":"2016","unstructured":"Ogawa W.; Sakaguchi K.; Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors. J Diabetes Investig  2016,7(2),135-138","journal-title":"J Diabetes Investig"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1210\/jc.2015-1884","volume":"100","author":"Taylor S.I.","year":"2015","unstructured":"Taylor S.I.; Blau J.E.; Rother K.I.; 104. Taylor SI, Blau JE, Rother KI. Perspective: SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab  2015,100(8),2849-2852","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1111\/anae.14251","volume":"73","author":"Milder D.A.","year":"2018","unstructured":"Milder D.A.; Milder T.Y.; Kam P.C.A.; Sodium-glucose co-transporter type-2 inhibitors: pharmacology and peri-operative considerations. Anaesthesia  2018,73(8),1008-1018","journal-title":"Anaesthesia"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1053\/j.ajkd.2014.02.010","volume":"64","year":"2014","unstructured":"GabbaiFB, LibertiME, etal.Sodium\/glucosecotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes. Am J Kidney Dis  2014,64,16-24","journal-title":"Am J Kidney Dis"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1210\/er.2010-0029","volume":"32","author":"Abdul-Ghani M.A.","year":"2011","unstructured":"Abdul-Ghani M.A.; Norton L.; DeFronzo R.A.; Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev  2011,32(4),515-531","journal-title":"Endocr Rev"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.jdiacomp.2016.05.008","volume":"30","author":"Palmer B.F.","year":"2016","unstructured":"Palmer B.F.; Clegg D.J.; Taylor S.I.; Weir M.R.; Diabetic ketoacidosis, sodium glucose transporter-2 inhibitors and the kidney. J Diabetes Complications  2016,30(6),1162-1166","journal-title":"J Diabetes Complications"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"Heerspink H.J.L.","year":"2016","unstructured":"Heerspink H.J.L.; Perkins B.A.; Fitchett D.H.; Husain M.; Cherney D.Z.I.; Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: Cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation  2016,134(10),752-772","journal-title":"Circulation"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1210\/jc.2015-3167","volume":"101","author":"Watts N.B.","year":"2016","unstructured":"Watts N.B.; Bilezikian J.P.; Usiskin K.; Edwards R.; Desai M.; Law G.; Meininger G.; Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab  2016,101(1),157-166","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1007\/s00125-013-3039-1","volume":"56","author":"Lavalle-Gonz\u00e1lez F.J.","year":"2013","unstructured":"Lavalle-Gonz\u00e1lez F.J.; Januszewicz A.; Davidson J.; Tong C.; Qiu R.; Canovatchel W.; Meininger G.; Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia  2013,56(12),2582-2592","journal-title":"Diabetologia"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/ki.2013.356","volume":"85","author":"Kohan D.E.","year":"2014","unstructured":"Kohan D.E.; Fioretto P.; Tang W.; List J.F.; Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int  2014,85(4),962-971","journal-title":"Kidney Int"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00125-019-05039-w","volume":"63","author":"Buse J.B.","year":"2020","unstructured":"Buse J.B.; Wexler D.J.; Tsapas A.; Rossing P.; Mingrone G.; Mathieu C.; D\u2019Alessio D.A.; Davies M.J.; 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia  2020,63(2),221-228","journal-title":"Diabetologia"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1210\/jc.2015-1860","volume":"101","author":"Bilezikian J.P.","year":"2016","unstructured":"Bilezikian J.P.; Watts N.B.; Usiskin K.; Polidori D.; Fung A.; Sullivan D.; Rosenthal N.; Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin. J Clin Endocrinol Metab  2016,101(1),44-51","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/dom.12273","volume":"16","author":"Forst T.","year":"2014","unstructured":"Forst T.; Guthrie R.; Goldenberg R.; Yee J.; Vijapurkar U.; Meininger G.; Stein P.; Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab  2014,16(5),467-477","journal-title":"Diabetes Obes Metab"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"420","DOI":"10.2337\/dc14-1096","volume":"38","author":"Tikkanen I.","year":"2015","unstructured":"Tikkanen I.; Narko K.; Zeller C.; Green A.; Salsali A.; Broedl U.C.; Woerle H.J.; Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care  2015,38(3),420-428","journal-title":"Diabetes Care"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","volume":"159","author":"Vasilakou D.","year":"2013","unstructured":"Vasilakou D.; Karagiannis T.; Athanasiadou E.; Mainou M.; Liakos A.; Bekiari E.; Sarigianni M.; Matthews D.R.; Tsapas A.; Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med  2013,159(4),262-274","journal-title":"Ann Intern Med"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/dom.12081","volume":"15","author":"Ferrannini E.","year":"2013","unstructured":"Ferrannini E.; Seman L.; Seewaldt-Becker E.; Hantel S.; Pinnetti S.; Woerle H.J.; A  hase , randomized, placebo-controlled study of the  inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab  2013,15(8),721-728","journal-title":"Diabetes Obes Metab"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"650","DOI":"10.2337\/dc08-1863","volume":"32","author":"List J.F.","year":"2009","unstructured":"List J.F.; Woo V.; Morales E.; Tang W.; Fiedorek F.T.; Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care  2009,32(4),650-657","journal-title":"Diabetes Care"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1681\/ASN.2019111168","volume":"31","author":"Jardine M.J.","year":"2020","unstructured":"Jardine M.J.; Zhou Z.; Mahaffey K.W.; Oshima M.; Agarwal R.; Bakris G.; Bajaj H.S.; Bull S.; Cannon C.P.; Charytan D.M.; de Zeeuw D.; Di Tanna G.L.; Greene T.; Heerspink H.J.L.; Levin A.; Neal B.; Pollock C.; Qiu R.; Sun T.; Wheeler D.C.; Zhang H.; Zinman B.; Rosenthal N.; Perkovic V.; Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: A secondary analysis of the credence randomized trial. J Am Soc Nephrol  2020,31(5),1128-1139","journal-title":"J Am Soc Nephrol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.2337\/dc17-1551","volume":"41","author":"Inzucchi S.E.","year":"2018","unstructured":"Inzucchi S.E.; Iliev H.; Pfarr E.; Zinman B.; Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial. Diabetes Care  2018,41(1),e4-e5","journal-title":"Diabetes Care"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s40261-016-0438-3","volume":"36","author":"Mellander A.","year":"2016","unstructured":"Mellander A.; Billger M.; Johnsson E.; Tr\u00e4ff A.K.; Yoshida S.; Johnsson K.; Hypersensitivity events, including potentially hypersensitivity-related skin events, with dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis. Clin Drug Investig  2016,36(11),925-933","journal-title":"Clin Drug Investig"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.numecd.2017.10.008","volume":"27","author":"Raschi E.","year":"2017","unstructured":"Raschi E.; Parisotto M.; Forcesi E.; La Placa M.; Marchesini G.; De Ponti F.; Poluzzi E.; Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems. Nutr Metab Cardiovasc Dis  2017,27(12),1098-1107","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"937","DOI":"10.7150\/ijms.22224","volume":"15","author":"Sakaeda T.","year":"2018","unstructured":"Sakaeda T.; Kobuchi S.; Yoshioka R.; Haruna M.; Takahata N.; Ito Y.; Sugano A.; Fukuzawa K.; Hayase T.; Hayakawa T.; Nakayama H.; Takaoka Y.; Tohkin M.; Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors. Int J Med Sci  2018,15(9),937-943","journal-title":"Int J Med Sci"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1111\/dme.13508","volume":"34","author":"Kumar S.","year":"2017","unstructured":"Kumar S.; Costello A.J.; Colman P.G.; Fournier\u2019s gangrene in a man on empagliflozin for treatment of Type 2 diabetes. Diabet Med  2017,34(11),1646-1648","journal-title":"Diabet Med"},{"key":"ref=97","unstructured":"FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes.  Available from:  https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm617360.htm(accessed on 31-7-2024)"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"Neal B.","year":"2017","unstructured":"Neal B.; Perkovic V.; Mahaffey K.W.; de Zeeuw D.; Fulcher G.; Erondu N.; Shaw W.; Law G.; Desai M.; Matthews D.R.; Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med  2017,377(7),644-657","journal-title":"N Engl J Med"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1161\/CIRCRESAHA.117.311588","volume":"122","author":"Scheen A.J.","year":"2018","unstructured":"Scheen A.J.; Cardiovascular effects of new oral glucose-lowering agents: DPP4 and SGLT-2 inhibitors. Circ Res  2018,122(10),1439-1459","journal-title":"Circ Res"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"Zelniker T.A.","year":"2019","unstructured":"Zelniker T.A.; Wiviott S.D.; Raz I.; Im K.; Goodrich E.L.; Bonaca M.P.; Mosenzon O.; Kato E.T.; Cahn A.; Furtado R.H.M.; Bhatt D.L.; Leiter L.A.; McGuire D.K.; Wilding J.P.H.; Sabatine M.S.; SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet  2019,393(10166),31-39","journal-title":"Lancet"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ahj.2018.08.016","volume":"206","author":"Cannon C.P.","year":"2018","unstructured":"Cannon C.P.; McGuire D.K.; Pratley R.; Dagogo-Jack S.; Mancuso J.; Huyck S.; Charbonnel B.; Shih W.J.; Gallo S.; Masiukiewicz U.; Golm G.; Cosentino F.; Lauring B.; Terra S.G.; Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV). Am Heart J  2018,206,11-23","journal-title":"Am Heart J"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"Kosiborod M.","year":"2017","unstructured":"Kosiborod M.; Cavender M.A.; Fu A.Z.; Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation  2017,136,249-259","journal-title":"Circulation"},{"key":"ref=103a","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1016\/j.jacc.2018.03.009","volume":"71","author":"Kosiborod M","year":"2018","unstructured":"Kosiborod M; Lam CSP; Kohsaka S;  Lower cardiovascular risk associated with SGLT-2i in >400,000 patients: the CVD-REAL 2 study. J Am Coll Cardiol  2018,71,2628-2639","journal-title":"J Am Coll Cardiol"},{"key":"ref=103b","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-007599","volume":"5","author":"Rawshani A.","year":"2015","unstructured":"Rawshani A.; Svensson A.M.; Rosengren A.; Zethelius B.; Eliasson B.; Gudbj\u00f6rnsdottir S.; Impact of ethnicity on progress of glycaemic control in 131 935 newly diagnosed patients with type 2 diabetes: a nationwide observational study from the Swedish National Diabetes Register. BMJ open  2015,5(6)","journal-title":"BMJ open"},{"key":"ref=104a","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1161\/CIRCULATIONAHA.117.031227","volume":"137","author":"Udell J.A.","year":"2018","unstructured":"Udell J.A.; Yuan Z.; Rush T.; Cardiovascular outcomes and risks after initiation of a sodium glucose co-transporter 2 inhibitor: Results from the EASEL population-based cohort study. Circulation  2018,137,1450-1459","journal-title":"Circulation"},{"key":"ref=104b","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/M18-3136","volume":"171","author":"Dave C.V.","year":"2019","unstructured":"Dave C.V.; Schneeweiss S.; Kim D.; Fralick M.; Tong A.; Patorno E.; Sodium\u2013glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study. Annals of internal medicine  2019,171(4),248-256","journal-title":"Annals of internal medicine"},{"key":"ref=105a","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s12933-023-02035-8","volume":"22","author":"Chen J.Y.","year":"2023","unstructured":"Chen J.Y.; Pan H.C.; Shiao C.C.; Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis. Cardiovasc Diabetol  2023,22(1),290","journal-title":"Cardiovasc Diabetol"},{"key":"ref=105b","first-page":"1771","volume":"10","author":"Patel D.K.","unstructured":"Patel D.K.; Strong J.; The pleiotropic effects of sodium\u2013glucose cotransporter-2 inhibitors: beyond the glycemic benefit. Diabetes Therapy 2019 Oct;  ,10,1771-1792","journal-title":"Diabetes Therapy 2019 Oct;"},{"key":"ref=106a","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.124.069568","volume":"149","author":"Patel S.M.","year":"2024","unstructured":"Patel S.M.; Kang Y.M.; Im K.; Sodium-Glucose Cotransporter- 2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis. Circulation  2024,149(23),1789-1801","journal-title":"Circulation"},{"key":"ref=106b","first-page":"11312","volume":"278","author":"Brown A.J.","unstructured":"Brown A.J.; Goldsworthy S.M.; Barnes A.A.; Eilert M.M.; Tcheang L.; Daniels D.; Muir A.I.; Wigglesworth M.J.; Kinghorn I.; Fraser N.J.; Pike N.B.; The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. Journal of Biological Chemistry 2003 Mar 28;  ,278(13),11312-11319","journal-title":"Journal of Biological Chemistry 2003 Mar 28;"},{"key":"ref=107","author":"Solmon S.","year":"2022","unstructured":"Solmon S.; Meta-analysis strengthens evidence for SGLT2 inhibitors\nin patients with heart failure Prespecified meta-analysis of\nDELIVER and EMPEROR-Preserved presented in a Hot Line Session\ntoday at ESC Congress 2022. ESC Press 2022.  2022"},{"key":"ref=107b","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S2213-8587(17)30258-9","volume":"5","author":"Birkeland K.I.","year":"2017","unstructured":"Birkeland K.I.; J\u00f8rgensen M.E.; Carstensen B.; Persson F.; Gulseth H.L.; Thuresson M.; Fenici P.; Nathanson D.; Nystr\u00f6m T.; Eriksson J.W.; Bodeg\u00e5rd J.; Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. The lancet Diabetes and endocrinology  2017,5(9),709-717","journal-title":"The lancet Diabetes and endocrinology"},{"key":"ref=108a","doi-asserted-by":"publisher","first-page":"15922","DOI":"10.1038\/s41598-023-42989-z","volume":"13","author":"Mavrakanas T.A.","year":"2023","unstructured":"Mavrakanas T.A.; Tsoukas M.A.; Brophy J.M.; Sharma A.; Gariani K.; SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis. Sci Rep  2023,13(1),15922","journal-title":"Sci Rep"},{"key":"ref=108b","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","volume":"4","author":"Frias J.P.","unstructured":"Frias J.P.; Guja C.; Hardy E.; Ahmed A.; Dong F.; Ohman P.; Jabbour S.A.; Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION- 8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. The lancet Diabetes and endocrinology 2016 Dec 1;  ,4(12),1004-1016","journal-title":"The lancet Diabetes and endocrinology 2016 Dec 1;"},{"key":"ref=109a","doi-asserted-by":"publisher","first-page":"1419729","DOI":"10.3389\/fphar.2024.1419729","volume":"15","author":"Huang L.","year":"2024","unstructured":"Huang L.; Hu R.; Zou H.; Relative efficacy of five SGLT2 inhibitors: a network meta-analysis of 20 cardiovascular and respiratory outcomes. Front Pharmacol  2024,15,1419729","journal-title":"Front Pharmacol"},{"key":"ref=109b","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1161\/CIRCULATIONAHA.120.050255","volume":"Dec 8 142","author":"Cosentino F.","year":"2020","unstructured":"Cosentino F.; Cannon C.P.; Cherney D.Z.; Masiukiewicz U.; Pratley R.; Dagogo-Jack S.; Frederich R.; Charbonnel B.; Mancuso J.; Shih W.J.; Terra S.G.; Efficacy of ertugliflozin on heart failure\u2013related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV Trial. Circulation  2020,Dec 8 142(23),2205-2215","journal-title":"Circulation"}],"container-title":["Current Drug Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0125899775332399240806101923","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/233122\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0125899775332399240806101923","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T06:05:43Z","timestamp":1741241143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/233122\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":116,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0125899775332399240806101923","relation":{},"ISSN":["2589-9775"],"issn-type":[{"value":"2589-9775","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-06-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}